This Article Full Text Full Text (PDF) CME: Take the course for this article: FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell... eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Google Scholar Articles by Demko, S. Articles by Pazdur, R. PubMed PubMed Citation Articles by Demko, S. Articles by Pazdur, R.

Regulatory Issues: FDA

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Division of Biologic Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Key Words. Chronic lymphocytic leukemia • Progressive disease • First-line therapy • Alemtuzumab • Chlorambucil

Correspondence: Suzanne Demko, P.A.-C., U.S. Food and Drug Administration, 10903 New Hampshire Avenue, WO#22 Room 2307, Mail Stop 2343, Silver Spring, Maryland 20993, USA. Telephone: 301-796-2108; Fax: 301-796-9849; e-mail: suzanne.demko{at}fda.hhs.gov

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

On September 19, 2007, the U.S. Food and Drug Administration granted regular approval and expanded labeling for alemtuzumab (Campath^®; Genzyme Corporation, Cambridge, MA) as single-agent treatment for B-cell chronic lymphocytic leukemia (B-CLL). Alemtuzumab was initially approved in 2001 under accelerated approval regulations. Conversion to regular approval was based on a single study submitted to verify clinical benefit. Efficacy and safety were demonstrated in an open-label, international, multicenter, randomized trial of 297 patients with previously untreated, Rai stage I–IV B-CLL experiencing progression of their disease. Patients were randomized to either alemtuzumab, 30 mg i.v. over 2 hours three times per week on alternate days for a maximum of 12 weeks, or chlorambucil, 40 mg/m² orally every 28 days for a maximum of 12 months. The progression-free survival time, the primary study endpoint, was significantly longer in the alemtuzumab arm than in the chlorambucil arm. Both the overall and complete response rates were also significantly higher in the alemtuzumab arm. No differences in survival were observed. There were no new safety signals identified in patients receiving alemtuzumab. The most serious, and sometimes fatal, toxicities of alemtuzumab are cytopenias, infusion reactions, and infections.